Solutions

• One-Stop CAR-T Therapy Development
  • Biomarker Identification & Selection
  • ScFv Generation
  • CAR Design & Construction
  • CAR-T Gene Packaging & Delivery
  • Replication-Competent Virus Testing
  • CAR Cell In Vitro Assay
  • CAR-T Preclinical In Vivo Assay
  • IND Development for CAR-T Cell Therapy
  • GMP Production for CAR-T Products
  • CAR Clinical Trial
  • One-Stop Canine CAR-T Therapy Development
  • One-Stop mRNA CAR-T Therapy Development
  • TRAC-CAR-T Cell Development
  • Modular CAR-T Cell Generation
  • One-Stop Silence™ CAR-T Cell Development
  • Vaccine Boosting CAR-T Cell Therapy
  • STAb-T Cell Therapy Development
  • CAR-T Therapy Development in the Non-Cancer Field
  • Anti-HIV CAR Cell Therapy Development
  • T Cell Activity Modulator Discovery
  • T Cell Programming
  • Virus Specific T Cell (VST) Development
  • Antibody-Coupled T Cell Receptor (ACTR) Development
  • Organoid-induced hPSC-original T Cell Differentiation
  • γδ T Cell Engineering
  • CAR-T CDMO
• One-Stop TCR-T Therapy Development
  • TCR Biomarker Identification & Selection
  • TCR Generation & Optimization
  • TCR Design & Construction
  • TCR Gene Packaging & Delivery
  • TCR In Vitro Assay
  • TCR-T Preclinical In Vivo Assay
  • TCR Clinical Application
  • TCR Analysis
  • TCR Tetramerization Construction
  • ScFv-TCR T Cell Therapy Development
  • AbTCR Development
  • Bispecific TCR Development
  • CER Development
• One-Stop CAR-MA Therapy Development
• One-Stop CAR-NK Therapy Development
  • One-Stop CAR-NKT Therapy Development
  • One-Stop UniCAR-NK Therapy Development
  • iPSC-derived CAR-NK Therapy Development
  • One-Stop TCR-NK Therapy Development
  • NK Cell Genetic Engineering
  • NK Cell Expansion
• One-Stop CAR-B Therapy Development
• One-Stop CAR-Monocyte Therapy Development
• One-Stop Cytokine Release Syndrome (CRS) Management
• TCR-Like Antibody Development
  • MHC/Peptide Complex Production
  • TCR-Like Antibody Discovery
  • TCR-Like Antibody Affinity Characterization
  • TCR-Like CAR Construction & Evaluation
• In Vivo Cell Engineering Development
  • In Vivo CAR-T Cell Engineering
  • In Vivo B Cell Engineering
  • In Vivo CAR-NK Cell Engineering
  • In Vivo CAR-M Cell Engineering
• One-Stop Allogeneic Cell Therapy Development
  • Allogeneic CAR-T Therapy Development
  • Allogeneic TCR-T Therapy Development
  • Allogeneic CAR-NK Therapy Development
  • Allogeneic CAR/TCR Cell Design & Engineering
  • Other Allogeneic Cell Therapy Development
• TCR/CAR/Antigen-Engineered Tregs Development
  • CAR-Treg Development
• Cancer Vaccine Development
  • Cancer Vaccine Discovery
  • Cancer Vaccine Engineering
  • Cancer Vaccine Analytical Characterization
  • Cancer Vaccine In Vivo Assessment
  • Cancer Vaccine GMP Manufacturing
  • Dendritic Cell Vaccine Development
• Immune Genotyping
  • HLA Typing
  • KIR Typing
  • HLA Testing
  • Dog DLA Genotyping
  • Guinea Pig GPLA Genotyping
  • Mouse H2 Genotyping
  • Rabbit RLA Genotyping
  • Rat RT1 Genotyping
  • Rhesus Macaque MHC Genotyping
• Other Services
  • Tumor-infiltrating Lymphocyte-based Antibody Discovery
• TIL Therapy Development
  • Special TIL Therapy Development

Peptide-DC Vaccine Boosting pMHC-directed CAR-T Cell Solutions

Online Inquiry

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

pMHC-directed CAR-T cells are a promising approach in cancer immunotherapy designed to target specific intracellular proteins that are presented by MHC molecules on the surface of cancer cells. Peptide-dendritic cell (DC)-based vaccines may help activate and enhance the function of CAR-T cells, potentially overcoming antigen heterogeneity and tumor escape mechanisms. Therefore, the combination of pMHC-directed CAR-T cells with a peptide-DC vaccine holds great potential for improving the efficacy and specificity of cancer immunotherapy, offering a potential synergistic effect in targeting and eliminating cancer cells. Additionally, the combination therapy may improve the persistence and effectiveness of CAR-T cells within the tumor microenvironment. At Creative Biolabs, we specialize in designing and optimizing tailored peptide-DC vaccine solutions to enhance the efficiency of pMHC-directed CAR-T cell therapy.

Fig.1 pMHC-directed CAR-T cells are boosted by DC vaccination.¹

Services

Our team of experts has extensive experience in the design and production of CAR-T cells, as well as in the development of peptide-DC vaccines. We provide one-stop solutions for the combination of the peptide-DC vaccine and pMHC-directed CAR-T cell therapy. We utilize state-of-the-art technology and innovative methods to analyze the activity of pMHC-directed CAR-T cells both in vitro and in vivo, including their ability to recognize and kill cancer cells, their proliferative capacity, and their cytokine production profile.

• Generation of CAR-T Cells

Creative Biolabs also offers a comprehensive range of pMHC-directed CAR-T cell development services, from the initial identification of the target peptide-MHC complex to the generation of a highly potent CAR-T cell product. Our services are tailored to meet the unique requirements of each client's research project.

• Generation of Peptide-DC Vaccine

We also offer peptide-DC vaccine development and characterization services, including peptide synthesis, loading of peptides onto DCs, and maturation of DCs. Our peptide-DC vaccines are designed to stimulate the immune system by presenting tumor-specific peptides in complex with MHC molecules to T cells. By combining these vaccines with pMHC-directed CAR-T cells, we aim to enhance anti-tumor immune responses and improve therapeutic outcomes.

• In Vitro Functional Analysis

Our in vitro CAR-T cell functional analysis services include assays to measure CAR-T cell proliferation, cytotoxicity, and cytokine production upon stimulation with the peptide-DC vaccine.

• In Vivo Functional Analysis

Our in vivo functional analysis service includes a comprehensive evaluation of pMHC-directed CAR-T cell activity in a mouse tumor model. We utilize state-of-the-art imaging techniques and immunological assays to assess tumor regression, CAR-T cell trafficking, and anti-tumor immune responses.

Highlights & Advantages

• Fully custom services to ensure that the most appropriate combination solution of CAR-T and vaccine
• One-stop solutions from CAR-T development, vaccine development, to in vitro and in vivo functional analysis
• State-of-the-art technology and methods to ensure consistency and efficiency throughout the process.
• Saves time and effort while maintaining the highest standards of quality

Contact Us

Our team's expertise in CAR-T cell design and production, coupled with our knowledge of peptide-DC vaccine development, ensures that our solutions are both effective and safe. By providing one-stop solutions for the combination of these two therapies, we aim to simplify the process for our clients, saving them time and effort. If you are interested in exploring the potential of DC vaccines to boost your CAR-T cell therapy, please contact us today.

Reference

1. Akahori, Yasushi, et al. "Antitumor activity of CAR-T cells targeting the intracellular oncoprotein WT1 can be enhanced by vaccination." Blood, The Journal of the American Society of Hematology 132.11 (2018): 1134-1145.